HER2-positive breast cancer (HER2+ BC) represents 15–20% of all BCs. In the last two
decades, the introduction of monoclonal antibodies (MoAbs), tyrosine kinase inhibitors …

Background There are two distinct types of gastric carcinoma (GC), intestinal, more
frequently sporadic and linked to environmental factors, and diffuse (undifferentiated) that is …

Introduction In the last decades, the therapeutic decision-making approach to metastatic
renal cell cancer (mRCC) has dramatically changed thanks to the introduction in the …

Abstract Purpose: Even if RAS-BRAF wild-type and HER2/MET–negative metastatic
colorectal cancer (mCRC) patients frequently respond to anti-EGFR mAbs, acquired …

Introduction. Right-and left-sided colorectal cancers (CRCs) differ in clinical and molecular
characteristics. Some retrospective analyses suggested that patients with right-sided tumors …

Simple Summary Several strategies have demonstrated the ability to improve the survival of
patients with both metastatic and nonmetastatic prostate cancer. The old backbone of …

Simple Summary Apalutamide, darolutamide and enzalutamide are androgen-receptor
signaling inhibitors proved to be useful in patients with nonmetastatic castration-resistant …

Platinum salts are active against metastatic triple negative breast cancer (mTNBC), and
biomarkers to predict their effectiveness are urgently needed. In recent years, the neutrophil …

Background: Breast cancer (BC) is the most common neoplasm in women. Many clinical and
preclinical studies investigated the possible relationship between host metabolism and BC …

Background. No prospective trials have specifically addressed the efficacy and safety of
panitumumab in elderly patients with metastatic colorectal cancer (CRC). We aimed at …